§ Federal grant opportunity · RFA-CA-26-010
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
National Institutes of Health is accepting applications for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed). The deadline is Rolling / not published and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- Rolling / not published
- Award range
- Award amount not published
- Eligibility
- other, public and state institutions of higher education, public and indian housing authorities, private institutions of higher education, other native american tribal organizations, city or township governments, small businesses, county governments, independent school districts, state governments, nonprofits non higher education with 501c3, for profit organizations other than small businesses, special district governments, federally recognized native american tribal governments, nonprofits non higher education without 501c3
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-CA-26-010
Program overview
The goal of this RFA is to continue to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. Pet dog patients develop cancer spontaneously and the courses of disease and treatment responses are similar to those in humans. Canine clinical trial results are translatable to humans. The assessment of responses to immunotherapy in immune-intact animals with existing cancers, such as pet dog patients, is the only way to preclinically take into account all facets of the immune response to cancer and to therapies. Ethically, pet dogs can benefit from the clinical trials by receiving cutting-edge therapies supported by the NIH, while providing important data informative to human disease. The network supported by this U01 RFA will consist of five U01 awards. One U01 will serve as a multifunctional Network Coordinating Center that will not only facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN) but will also perform limited research to support the network. Four U01 recipients will conduct canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities. Through this reissue Notice of Funding Opportunity, the National Cancer Institute intends to continue to support canine immunotherapeutic development as the field continues to grow, in part because of NIH funding. In the last five years, canine immunotherapeutics such as immune checkpoint inhibitors have become available as have canine analytics, development of which were partially supported by NCI. The goal is to maintain the momentum for further development of canine analytics and therapeutics and the ability to evaluate novel and repurposed drugs, treatment combinations, and treatment dosing and sequencing in pet dogs in a timely fashion. This NOFO consolidates the prior U01 (RFA-CA-21-050) and U24 (RFA-CA-21-051) funding opportunities to streamline the application process for continued support to K9CIN. Applicants have the option of submitting either for the Network Coordinating Center with limited research focus or for conducting canine cancer immunotherapy clinical trials and correlative studies. These important canine cancer-related activities will provide a valuable opportunity for NIH support to benefit humans and dogs, at both ends of the leash.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before Rolling / not published, allowing time for registration and validation.
Related grant opportunities
- Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Single source: Childhood Cancer Survivor Study (U24 Clinical Trial Not Allowed)
- Long Range Broad Agency Announcement (BAA) for NSWC Crane
- NSF Astronomy and Astrophysics Postdoctoral Fellowships (AAPF)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.